1
|
DeSantis CE, Siegel RL, Sauer AG, Miller
KD, Fedewa SA, Alcaraz KI and Jemal A: Cancer statistics for
African Americans, 2016: Progress and opportunities in reducing
racial disparities. CA Cancer J Clin. 66:290–308. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Feldman BJ and Feldman D: The development
of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45.
2001. View
Article : Google Scholar : PubMed/NCBI
|
3
|
Saraon P, Jarvi K and Diamandis EP:
Molecular alterations during progression of prostate cancer to
androgen independence. Clin Chem. 57:1366–1375. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Yuan X and Balk SP: Mechanisms mediating
androgen receptor reactivation after castration. Urol Oncol.
27:36–41. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Cohen MB and Rokhlin OW: Mechanisms of
prostate cancer cell survival after inhibition of AR expression. J
Cell Biochem. 106:363–371. 2009. View Article : Google Scholar : PubMed/NCBI
|
6
|
Horii T and Hatada I: Genome engineering
using the CRISPR/Cas system. World J Med Genet. 4:69–76. 2014.
View Article : Google Scholar
|
7
|
Mali P, Yang L, Esvelt KM, Aach J, Guell
M, DiCarlo JE, Norville JE and Church GM: RNA-guided human genome
engineering via Cas9. Science. 339:823–826. 2013. View Article : Google Scholar : PubMed/NCBI
|
8
|
Pu J, Frescas D, Zhang B and Feng J:
Utilization of TALEN and CRISPR/Cas9 technologies for gene
targeting and modification. Exp Biol Med (Maywood). 240:1065–1070.
2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Seeger C and Sohn JA: Targeting hepatitis
B virus with CRISPR/Cas9. Mol Ther Nucleic Acids. 3:e2162014.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Lu XJ, Qi X, Zheng DH and Ji LJ: Modeling
cancer processes with CRISPR-Cas9. Trends Biotechnol. 33:317–319.
2015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Tang H and Shrager JB: CRISPR/Cas-mediated
genome editing to treat EGFR-mutant lung cancer: A personalized
molecular surgical therapy. EMBO Mol Med. 8:83–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
12
|
Matano M, Date S, Shimokawa M, Takano A,
Fujii M, Ohta Y, Watanabe T, Kanai T and Sato T: Modeling
colorectal cancer using CRISPR-Cas9-mediated engineering of human
intestinal organoids. Nat Med. 21:256–262. 2015.PubMed/NCBI
|
13
|
Wang G, Zhao N, Berkhout B and Das AT:
CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair
facilitates virus escape. Mol Ther. 24:522–526. 2016. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kawamura N, Nimura K, Nagano H, Yamaguchi
S, Nonomura N and Kaneda Y: CRISPR/Cas9-mediated gene knockout of
NANOG and NANOGP8 decreases the malignant potential of prostate
cancer cells. Oncotarget. 6:22361–22374. 2015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Zhang HT, Jun WU, Zhang HF and Zhu QF:
Efflux of potassium ion is an important reason of HL-60 cells
apoptosis induced by tachyplesin. Acta Pharmacol Sin. 27:1367–1374.
2006. View Article : Google Scholar : PubMed/NCBI
|
16
|
Heinlein CA and Chang C: Androgen receptor
in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
|
17
|
Shore N: Management of early-stage
prostate cancer. Am J Manag Care. 20 12 Suppl:S260–S272.
2014.PubMed/NCBI
|
18
|
Yu L, Wang X, Zhu D, Ding W, Wang L, Zhang
C, Jiang X, Shen H, Liao S, Ma D, et al: Disruption of human
papillomavirus 16 E6 gene by clustered regularly interspaced short
palindromic repeat/Cas system in human cervical cancer cells. Onco
Targets Ther. 8:37–44. 2014.PubMed/NCBI
|
19
|
Hu Z, Yu L, Zhu D, Ding W, Wang X, Zhang
C, Wang L, Jiang X, Shen H, He D, et al: Disruption of HPV16-E7 by
CRISPR/Cas system induces apoptosis and growth inhibition in HPV16
positive human cervical cancer cells. Biomed Res Int 2014.
6128232014.
|
20
|
Ding Q, Regan SN, Xia Y, Oostrom LA, Cowan
CA and Musunuru K: Enhanced efficiency of human pluripotent stem
cell genome editing through replacing TALENs with CRISPRs. Cell
Stem Cell. 12:393–394. 2013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Pattanayak V, Guilinger JP and Liu DR:
Determining the specificities of TALENs, Cas9, and other genome
editing enzymes. Methods Enzymol. 546:47–78. 2014. View Article : Google Scholar : PubMed/NCBI
|